康宁杰瑞制药-B（09966）今日盘中大涨6.22%，引起投资者广泛关注。截至发稿时，该股报价7.8港元，成交额达1841.92万港元。
此次股价上涨主要受公司近期公布的年度业绩推动。康宁杰瑞制药发布的年报显示，公司2024年全年收入达人民币6.4亿元，同比大幅增长192.58%；更值得注意的是，公司实现扭亏为盈，年度溢利达人民币1.66亿元。公司表示，这一亮眼业绩主要得益于三项授权合作和销售收入的增长。
除了财务业绩的显著改善，康宁杰瑞制药近期还传出另一利好消息。公司的HER2双特异性抗体偶联药物（ADC）JSKN003获得国家药品监督管理局（NMPA）药品审评中心（CDE）授予的突破性疗法认定，用于治疗铂耐药复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌，且不限HER2表达水平。这一认定有望加快JSKN003的临床开发和审评审批进程，进一步增强了投资者对公司未来发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.